Person: NADİR, AYDIN
Search Results
The frequency, serial changes and clinical characteristics of cardiac troponin release in patients with acute heart failure syndrome
2011-08-01T00:00:00Z, ÇAVUŞOĞLU, YÜKSEL, Gencer, E., Tek, M., BİLGİN, MUZAFFER, Nadiradze, AYDIN, BİRDANE, ALPARSLAN, GÖRENEK, BÜLENT, Unalir, A., ATA, NECMİ, NADİR, AYDIN
Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure
2015-09-01T00:00:00Z, ÇAVUŞOĞLU, YÜKSEL, MERT, KADİR UĞUR, Nadir, AYDIN, MUTLU, FEZAN, Morrad, Bektas, ULUS, TANER, NADİR, AYDIN
Background Ivabradine is a heart rate (HR)-lowering agent acting by inhibiting the I-f-channel. Dobutamine does increase the HR and has some deleterious effects on myocardium. So, we aimed to evaluate whether ivabradine treatment blunts a dobutamine-induced increase in HR.
Ivabradine Treatment Blunts Dobutamine-Induced Increase in Heart Rate in Patients with Acute Decompensated Heart Failure: A Comparative Study with Beta-Blocker Therapy
2013-10-01T00:00:00Z, ÇAVUŞOĞLU, YÜKSEL, MERT, KADİR UĞUR, Nadir, AYDIN, MUTLU, FEZAN, Gencer, Erkan, Morrad, Bektas, ULUS, TANER, NADİR, AYDIN
Levosimendan and Dobutamine are Equally Effective in Improving Functional Status in Patients Hospitalized with Acute Decompensated Heart Failure
2012-11-01T00:00:00Z, ÇAVUŞOĞLU, YÜKSEL, Nadir, AYDIN, MERT, KADİR UĞUR, MUTLU, FEZAN, ULUS, TANER, Doksoz, Ahmet, Yunus, Ozge, Huseyinoglu, Ayse, Senol, Utku, Unalir, Ahmet, NADİR, AYDIN
Ivabradine effectively prevents heart rate increase, however, has no effect on cardiac arrhythmias during dobutamine infusion: a comparative study with beta-blocker therapy
2013-08-01T00:00:00Z, ÇAVUŞOĞLU, YÜKSEL, MERT, KADİR UĞUR, Nadir, AYDIN, MUTLU, FEZAN, ULUS, TANER, Unalir, A., NADİR, AYDIN
Ivabradine treatment blunts dobutamine-induced increase in heart rate in patients with acute decompensated heart failure: a comparative study with beta-blocker therapy
2013-05-01T00:00:00Z, ÇAVUŞOĞLU, YÜKSEL, MERT, KADİR UĞUR, Nadir, AYDIN, MUTLU, FEZAN, Gencer, E., ULUS, TANER, NADİR, AYDIN
Subclinical Myocardial Dysfunction in Patients with Pseudoexfoliation Syndrome: A Tissue Doppler Study
2012-11-01T00:00:00Z, ULUS, TANER, Nadir, AYDIN, Nasifov, Muharrem, Senol, Utku, Yazici, Huseyin Ugur, BİRDANE, ALPARSLAN, ÇAVUŞOĞLU, YÜKSEL, Unalir, Ahmet, NADİR, AYDIN
Effects of levosimendan and dobutamine on systolic time intervals in patients with acute decompensated heart failure
2013-05-01T00:00:00Z, ÇAVUŞOĞLU, YÜKSEL, Nadir, AYDIN, MERT, KADİR UĞUR, Gencer, E., MUTLU, FEZAN, ULUS, TANER, NADİR, AYDIN
Ivabradine has no Effect on Cardiac Arrhythmias Observed During Dobutamine Infusion: A Comparative Study with beta Blocker Therapy
2013-10-01T00:00:00Z, ÇAVUŞOĞLU, YÜKSEL, MERT, KADİR UĞUR, Nadir, AYDIN, MUTLU, FEZAN, Morrad, Bektas, ULUS, TANER, NADİR, AYDIN
Comparison of the Effects of Levosimendan Dobutamine and Vasodilator Therapy on Ongoing Myocardial Injury in Acute Decompensated Heart Failure
2017-03-01T00:00:00Z, Gencer, Erkan, Dogan, Volkan, Ozturk, Mujgan Tek, Nadir, AYDIN, MUSMUL, AHMET, ÇAVUŞOĞLU, YÜKSEL, NADİR, AYDIN
Background: Cardiac troponins (cTn) are reliable and the most sensitive biomarker in the setting of acute decompensated heart failure (ADHF). Acute decompensated heart failure is usually associated with worsening chronic heart failure, and it may be caused by ongoing minor myocardial cell damage that may occur without any reported precipitating factors. Methods: We compared the short-term effect of levosimendan (LEV), dobutamine (DOB), and vasodilator treatment (nitroglycerin [NTG]) on myocardial injury with hemodynamic, neurohumoral, and inflammatory indicators. One hundred twenty-two patients with a mean age of 66 +/- 9 years were treated with LEV (n = 40), DOB (n = 42), and NTG (n = 40) and examined retrospectively. Blood samples (cTnI, N-terminal probrain natriuretic peptide [NT-proBNP], highly sensitive C-reactive protein [HsCRP], and others), left ventricular ejection fraction (LVEF), systolic pulmonary artery pressure (sPAP), and 6-minute walk distance (6MWD) were compared before and after treatment. Results: At admission, detectable levels of cTnI were observed in 53% of patients (>= 0.05 ng/mL). Serial changes in the mean cTnI levels were not significantly different between the groups (LEV 0.04 +/- 0.01 to 0.03 +/- 0.01 ng/mL; DOB 0.145 +/- 0.08 to 0.08 +/- 0.03 ng/mL; NTG 0.1 +/- 0.03 to 0.09 +/- 0.02 ng/mL; overall P = .859). Favourable effects on the NT-proBNP, sPAP values, LVEF, 6MWD, and HsCRP were observed overall, especially in the LEV groups. Conclusion: Beneficial effects of short-term use of LEV, DOB, and NTG on ongoing myocardial injury were demonstrated. These findings can be attributed to the anti-ischemic properties as well as the hemodynamic, neurohumoral, and functional benefits from the positive inotropes, especially LEV, in patients with ADHF.